Immunotherapy after standard care may delay lung cancer return
NCT ID NCT02316002
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the immunotherapy drug pembrolizumab (Keytruda) can help people with oligometastatic non-small cell lung cancer (NSCLC) who have already completed curative treatment. Fifty-one participants received pembrolizumab every three weeks for up to 16 cycles. The main goal was to see how long they lived without the cancer growing or spreading. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (a drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could show that adding pembrolizumab after standard treatment helps keep lung cancer from coming back longer.
- What could go wrong
- This is a small Phase 2 study with only 51 participants, so results may not apply to everyone. Pembrolizumab can cause immune-related side effects like inflammation in the lungs, colon, or skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.